ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION FOR NON-HODGKIN’S LYMPHOMASA RETROSPECTIVE ANALYSIS OF 77 CASES
(Abstract release date: 05/19/16)
EHA Library. Patrascu A. 06/09/16; 133094; E1545
Mrs. Ana-Maria Patrascu
Contributions
Contributions
Abstract
Abstract: E1545
Type: Eposter Presentation
Background
Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of malignancies characterized by uncontrolled proliferation of clonal lymphocytes, which have varied aggressiveness. Allogeneic stem-cell transplantation (allo-SCT) is a therapeutic option for advanced and otherwise incurable NHL. The major drawbacks associated with this therapy are graft-versus-host disease (GVHD) and infections. On the positive side, it is becoming clear that in the allo-SCT setting there is a graft-versus-lymphoma effect. Selection of the appropriate patients and donors, as well as the transplantation timing still is a matter of debate.
Aims
To investigate the factors that influenced the outcome after allo-SCT for NHL over a 20 years period in a Spanish University hospital
Methods
Retrospective analysis of patients with NHL who received an allo-SCT between January 1995 and December 2014. Statistical analyses were performed using the IBM SPSS Statistics version 21. Survival curves were estimated by the Kaplan-Meier method and compared using the log-rank test. Variables were selected based on previous studies: age (≤60 vs. >60 years), gender (male vs. female), previous ASCT, disease status pre allo-SCT, number of chemotherapy lines before allo-SCT, intensity of conditioning regimen (ablative vs. reduced intensity), HLA compatibility (no mismatch vs mismatch), related donor vs. unrelated donor. Cox regression method was used to develop a prognostic model of OS.
Results
The characteristics of the series are summarized in Table 1.Indolent NHL (iNHL) accounted for 43% of patients (n=33) and aggressive NHL 57% (n= 44). Within aggressive NHL, 16% were of T-cell origin.The median time follow-up after alloSCT was 23 months (range 0 – 232). The OS at median time was 53.5% and the PFS was 53.8 % (only 9 progressed). The main cause of death (n= 48) were GVHD 37.5% (n=18), infections 22.9% (n=11), secondary malignancies 8.3% (n=4) and veno-oclussive disease 4.2% (n=2).Age and response pre allo-SCT had statistically significant impact on OS in multivariate analysis (p<0.01) The OS for patients ≤60 years old vs.>60 years old were 58.% and 24%, respectively.The OS for patients in CR pre allo-SCT was 60% and for patients in PR was 55%. All patients with progressive disease were death at median time of follow-up.
Conclusion
Allo-SCT is a feasible option for high risk of relapse lymphoma patients. Old patients and those with non-responsive disease before allo-SCT should be considered for alternative therapies. The results are remarkable in younger patients with sensitive NHL.
Session topic: E-poster
Keyword(s): Allogeneic hematopoietic stem cell transplant, Non-Hodgkin's lymphoma
Type: Eposter Presentation
Background
Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of malignancies characterized by uncontrolled proliferation of clonal lymphocytes, which have varied aggressiveness. Allogeneic stem-cell transplantation (allo-SCT) is a therapeutic option for advanced and otherwise incurable NHL. The major drawbacks associated with this therapy are graft-versus-host disease (GVHD) and infections. On the positive side, it is becoming clear that in the allo-SCT setting there is a graft-versus-lymphoma effect. Selection of the appropriate patients and donors, as well as the transplantation timing still is a matter of debate.
Aims
To investigate the factors that influenced the outcome after allo-SCT for NHL over a 20 years period in a Spanish University hospital
Methods
Retrospective analysis of patients with NHL who received an allo-SCT between January 1995 and December 2014. Statistical analyses were performed using the IBM SPSS Statistics version 21. Survival curves were estimated by the Kaplan-Meier method and compared using the log-rank test. Variables were selected based on previous studies: age (≤60 vs. >60 years), gender (male vs. female), previous ASCT, disease status pre allo-SCT, number of chemotherapy lines before allo-SCT, intensity of conditioning regimen (ablative vs. reduced intensity), HLA compatibility (no mismatch vs mismatch), related donor vs. unrelated donor. Cox regression method was used to develop a prognostic model of OS.
Results
The characteristics of the series are summarized in Table 1.Indolent NHL (iNHL) accounted for 43% of patients (n=33) and aggressive NHL 57% (n= 44). Within aggressive NHL, 16% were of T-cell origin.The median time follow-up after alloSCT was 23 months (range 0 – 232). The OS at median time was 53.5% and the PFS was 53.8 % (only 9 progressed). The main cause of death (n= 48) were GVHD 37.5% (n=18), infections 22.9% (n=11), secondary malignancies 8.3% (n=4) and veno-oclussive disease 4.2% (n=2).Age and response pre allo-SCT had statistically significant impact on OS in multivariate analysis (p<0.01) The OS for patients ≤60 years old vs.>60 years old were 58.% and 24%, respectively.The OS for patients in CR pre allo-SCT was 60% and for patients in PR was 55%. All patients with progressive disease were death at median time of follow-up.
Conclusion
Allo-SCT is a feasible option for high risk of relapse lymphoma patients. Old patients and those with non-responsive disease before allo-SCT should be considered for alternative therapies. The results are remarkable in younger patients with sensitive NHL.
Session topic: E-poster
Keyword(s): Allogeneic hematopoietic stem cell transplant, Non-Hodgkin's lymphoma
Abstract: E1545
Type: Eposter Presentation
Background
Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of malignancies characterized by uncontrolled proliferation of clonal lymphocytes, which have varied aggressiveness. Allogeneic stem-cell transplantation (allo-SCT) is a therapeutic option for advanced and otherwise incurable NHL. The major drawbacks associated with this therapy are graft-versus-host disease (GVHD) and infections. On the positive side, it is becoming clear that in the allo-SCT setting there is a graft-versus-lymphoma effect. Selection of the appropriate patients and donors, as well as the transplantation timing still is a matter of debate.
Aims
To investigate the factors that influenced the outcome after allo-SCT for NHL over a 20 years period in a Spanish University hospital
Methods
Retrospective analysis of patients with NHL who received an allo-SCT between January 1995 and December 2014. Statistical analyses were performed using the IBM SPSS Statistics version 21. Survival curves were estimated by the Kaplan-Meier method and compared using the log-rank test. Variables were selected based on previous studies: age (≤60 vs. >60 years), gender (male vs. female), previous ASCT, disease status pre allo-SCT, number of chemotherapy lines before allo-SCT, intensity of conditioning regimen (ablative vs. reduced intensity), HLA compatibility (no mismatch vs mismatch), related donor vs. unrelated donor. Cox regression method was used to develop a prognostic model of OS.
Results
The characteristics of the series are summarized in Table 1.Indolent NHL (iNHL) accounted for 43% of patients (n=33) and aggressive NHL 57% (n= 44). Within aggressive NHL, 16% were of T-cell origin.The median time follow-up after alloSCT was 23 months (range 0 – 232). The OS at median time was 53.5% and the PFS was 53.8 % (only 9 progressed). The main cause of death (n= 48) were GVHD 37.5% (n=18), infections 22.9% (n=11), secondary malignancies 8.3% (n=4) and veno-oclussive disease 4.2% (n=2).Age and response pre allo-SCT had statistically significant impact on OS in multivariate analysis (p<0.01) The OS for patients ≤60 years old vs.>60 years old were 58.% and 24%, respectively.The OS for patients in CR pre allo-SCT was 60% and for patients in PR was 55%. All patients with progressive disease were death at median time of follow-up.
Conclusion
Allo-SCT is a feasible option for high risk of relapse lymphoma patients. Old patients and those with non-responsive disease before allo-SCT should be considered for alternative therapies. The results are remarkable in younger patients with sensitive NHL.
Session topic: E-poster
Keyword(s): Allogeneic hematopoietic stem cell transplant, Non-Hodgkin's lymphoma
Type: Eposter Presentation
Background
Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of malignancies characterized by uncontrolled proliferation of clonal lymphocytes, which have varied aggressiveness. Allogeneic stem-cell transplantation (allo-SCT) is a therapeutic option for advanced and otherwise incurable NHL. The major drawbacks associated with this therapy are graft-versus-host disease (GVHD) and infections. On the positive side, it is becoming clear that in the allo-SCT setting there is a graft-versus-lymphoma effect. Selection of the appropriate patients and donors, as well as the transplantation timing still is a matter of debate.
Aims
To investigate the factors that influenced the outcome after allo-SCT for NHL over a 20 years period in a Spanish University hospital
Methods
Retrospective analysis of patients with NHL who received an allo-SCT between January 1995 and December 2014. Statistical analyses were performed using the IBM SPSS Statistics version 21. Survival curves were estimated by the Kaplan-Meier method and compared using the log-rank test. Variables were selected based on previous studies: age (≤60 vs. >60 years), gender (male vs. female), previous ASCT, disease status pre allo-SCT, number of chemotherapy lines before allo-SCT, intensity of conditioning regimen (ablative vs. reduced intensity), HLA compatibility (no mismatch vs mismatch), related donor vs. unrelated donor. Cox regression method was used to develop a prognostic model of OS.
Results
The characteristics of the series are summarized in Table 1.Indolent NHL (iNHL) accounted for 43% of patients (n=33) and aggressive NHL 57% (n= 44). Within aggressive NHL, 16% were of T-cell origin.The median time follow-up after alloSCT was 23 months (range 0 – 232). The OS at median time was 53.5% and the PFS was 53.8 % (only 9 progressed). The main cause of death (n= 48) were GVHD 37.5% (n=18), infections 22.9% (n=11), secondary malignancies 8.3% (n=4) and veno-oclussive disease 4.2% (n=2).Age and response pre allo-SCT had statistically significant impact on OS in multivariate analysis (p<0.01) The OS for patients ≤60 years old vs.>60 years old were 58.% and 24%, respectively.The OS for patients in CR pre allo-SCT was 60% and for patients in PR was 55%. All patients with progressive disease were death at median time of follow-up.
Conclusion
Allo-SCT is a feasible option for high risk of relapse lymphoma patients. Old patients and those with non-responsive disease before allo-SCT should be considered for alternative therapies. The results are remarkable in younger patients with sensitive NHL.
Session topic: E-poster
Keyword(s): Allogeneic hematopoietic stem cell transplant, Non-Hodgkin's lymphoma
{{ help_message }}
{{filter}}